罗伊氏乳杆菌益生菌辅助治疗糖尿病牙周炎患者:随机临床试验
这项为期6个月、三盲、随机临床试验纳入40例未经治疗的糖尿病牙周炎患者,在龈下刮治后分别服用罗伊氏乳杆菌益生菌片或安慰剂3个月。6个月时两组平均探诊深度均显著降低(益生菌组0.9 mm,安慰剂组0.8 mm),组间无显著差异;但益生菌组HbA1c降幅更大(-0.6% vs -0.1%),组间差异有统计学意义(-0.5%;95%CI [-1.0; 0.0];p < 0.001)。微生物学结局两组相似。
要点
- 罗伊氏乳杆菌辅助龈下刮治未额外改善糖尿病牙周炎患者的临床或微生物学结局。
- 益生菌组6个月HbA1c降幅大于安慰剂组,提示潜在全身获益。
- 研究为三盲随机对照试验,样本量40例,随访6个月。
核心结论
- 在糖尿病牙周炎患者中,罗伊氏乳杆菌益生菌辅助龈下刮治未比安慰剂带来额外临床或微生物学获益。
- 但益生菌组HbA1c降幅显著大于安慰剂组,提示可能存在全身性获益。
研究设计与样本
- 为期6个月、随机、三盲临床试验,纳入40例未经治疗的糖尿病牙周炎患者。
- 所有患者接受牙周治疗第一步和第二步(包括龈下刮治),随机服用罗伊氏乳杆菌片或安慰剂3个月。
- 在基线、治疗后3个月和6个月评估临床、微生物学结局及HbA1c浓度。
主要发现
- 6个月时两组主要结局(平均探诊深度)均显著降低:益生菌组0.9 mm,安慰剂组0.8 mm,组间无显著差异。
- 6个月时两组HbA1c均降低,益生菌组降幅更大(-0.6% vs -0.1%),组间差异有统计学意义(-0.5%;95%CI [-1.0; 0.0];p < 0.001)。
- 微生物学结局两组相似。
临床怎么用
- 对于糖尿病牙周炎患者,不应期望罗伊氏乳杆菌辅助龈下刮治能额外改善临床或微生物学指标。
- 益生菌辅助可能有助于改善HbA1c,但需结合患者个体情况和进一步证据谨慎解读。
局限性
- 样本量较小(40例),可能影响结果的普遍性。
- 随访期仅6个月,长期效果未知。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: To evaluate the clinical and microbiological effects of a Limosilactobacillus reuteri-based probiotic as an adjunct to subgingival instrumentation in untreated periodontitis patients with diabetes. METHODS: A 6-month, randomised, triple-blinded clinical trial was conducted involving 40 patients, receiving steps 1 and 2 of periodontal therapy, including subgingival instrumentation, and randomised to receive tablets containing L. reuteri or placebo, for 3 months. Clinical and microbiological outcomes as well as glycosylated haemoglobin (HbA1c) concentrations were evaluated at baseline and at 3 and 6 months after therapy. RESULTS: At 6 months, both groups showed statistically significant reductions in the primary outcome (mean probing depth), with reductions of 0.9 mm in the probiotic group and 0.8 mm in the placebo group, with no significant differences between them. Both groups exhibited reductions in HbA1c levels after 6 months, more in the probiotic group (-0.6% vs. -0.1%), with statistically significant inter-group differences (-0.5%; 95% confidence interval [-1.0; 0.0]; p < 0.001). Microbiological outcomes were similar. CONCLUSIONS: The adjunctive use of a L. reuteri-based probiotic did not provide additional clinical or microbiological benefits, compared to placebo, following subgingival instrumentation in patients with periodontitis and diabetes. However, statistically significant differences in HbA1c levels were observed, with larger reductions in the probiotic group, suggesting a potential systemic benefit. TRIAL REGISTRATION: The protocol was approved by the Clinical Research Ethics Committee (CEIC) of Hospital Clínico de San Carlos (internal code 19/101-R_X) and registered a priori in ClinicalTrials.gov (identifier NCT04069611).
引用
- Bujaldón R, Montero E, Gamonal JD, et al. Use of the Probiotic Limosilactobacillus reuteri as an Adjunct to Subgingival Instrumentation in the Treatment of Periodontitis Patients With Diabetes: A Randomised Clinical Trial. J Clin Periodontol. 2025. PMID: 40958659. doi:10.1111/jcpe.70035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。